Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism
Conditions: Chronic Thromboembolic Pulmonary Hypertension Sponsors: Ester Ashraf Faried Beshay Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 13, 2023 Category: Research Source Type: clinical trials

Hemodynamic Effect of Nasal High-flow in Patients Suspected or Followed for a Precapillary Pulmonary Hypertension
Conditions: Pulmonary Hypertension Interventions: Device: Nasal high-flow Sponsors: ADIR Association Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 12, 2023 Category: Research Source Type: clinical trials

HA Residents With PVD, SDB Assessed at HA (2840m) vs LA (Sea Level)
Conditions: Pulmonary Vascular Disease; Pulmonary Artery Hypertension; Chronic Thromboembolic Pulmonary Hypertension Interventions: Other: Assessment without intervention at High altitude; Other: Relocation to sea level for 2 days Sponsors: University of Zurich Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 9, 2023 Category: Research Source Type: clinical trials

Impact of Pulmonary Endarterectomy on Sleep-Related Breathing Disorders
Conditions: Sleep-Disordered Breathing; Chronic Thromboembolic Pulmonary Hypertension; Post Operative Interventions: Procedure: Pulmonary endarterectomy Sponsors: Marmara University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials

Impact of Pulmonary Endarterectomy on Sleep-Related Breathing Disorders in CTEPH: The IPES Trial
Conditions: Sleep-Disordered Breathing; Chronic Thromboembolic Pulmonary Hypertension; Post Operative Interventions: Procedure: Pulmonary endarterectomy Sponsors: Marmara University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials

Repurposing Valsartan May Protect Against Pulmonary Hypertension
Conditions:   Pulmonary Arterial Hypertension;   Right Heart Failure;   Right Ventricular Dysfunction;   Pulmonary Vascular Disorder Interventions:   Drug: Valsartan 40 mg;   Drug: Placebo Sponsors:   University of Washington;   National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials

Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study)
Conditions:   Group 2 Pulmonary Hypertension;   Heart Failure Intervention:   Device: Gradient Denervation System Sponsor:   Gradient Denervation Technologies Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials

Repurposing Valsartan May Protect Against Pulmonary Hypertension
Conditions:   Pulmonary Arterial Hypertension;   Right Heart Failure;   Right Ventricular Dysfunction;   Pulmonary Vascular Disorder Interventions:   Drug: Valsartan 40 mg;   Drug: Placebo Sponsors:   University of Washington;   National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials

Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study)
Conditions:   Group 2 Pulmonary Hypertension;   Heart Failure Intervention:   Device: Gradient Denervation System Sponsor:   Gradient Denervation Technologies Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials

Repurposing Valsartan May Protect Against Pulmonary Hypertension
Conditions:   Pulmonary Arterial Hypertension;   Right Heart Failure;   Right Ventricular Dysfunction;   Pulmonary Vascular Disorder Interventions:   Drug: Valsartan 40 mg;   Drug: Placebo Sponsors:   University of Washington;   National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials

Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study)
Conditions:   Group 2 Pulmonary Hypertension;   Heart Failure Intervention:   Device: Gradient Denervation System Sponsor:   Gradient Denervation Technologies Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials

Repurposing Valsartan May Protect Against Pulmonary Hypertension
Conditions:   Pulmonary Arterial Hypertension;   Right Heart Failure;   Right Ventricular Dysfunction;   Pulmonary Vascular Disorder Interventions:   Drug: Valsartan 40 mg;   Drug: Placebo Sponsors:   University of Washington;   National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials

Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study)
Conditions:   Group 2 Pulmonary Hypertension;   Heart Failure Intervention:   Device: Gradient Denervation System Sponsor:   Gradient Denervation Technologies Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials

Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study)
Conditions: Group 2 Pulmonary Hypertension; Heart Failure Interventions: Device: Gradient Denervation System Sponsors: Gradient Denervation Technologies Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials

Repurposing Valsartan May Protect Against Pulmonary Hypertension
Conditions: Pulmonary Arterial Hypertension; Right Heart Failure; Right Ventricular Dysfunction; Pulmonary Vascular Disorder Interventions: Drug: Valsartan 40 mg; Drug: Placebo Sponsors: University of Washington; National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials